These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 34721981)
21. FGF 23, PTH and vitamin D status in end stage renal disease patients affected by VDR FokI and BsmI variants. Bouksila M; Kaabachi W; Mrad M; Smaoui W; El Kateb EC; Zouaghi MK; Hamzaoui K; Bahlous A Clin Biochem; 2018 Apr; 54():42-50. PubMed ID: 29458003 [TBL] [Abstract][Full Text] [Related]
22. Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD. Zhang LN; Yang G; Cheng C; Shen C; Cui YY; Zhang J; Zhang JJ; Shen ZX; Zeng M; Ge YF; Sun B; Yu XB; Ouyang C; Zhang B; Mao HJ; Liu J; Xing CY; Zha XM; Wang NN Osteoporos Int; 2015 Jan; 26(1):395-405. PubMed ID: 25224292 [TBL] [Abstract][Full Text] [Related]
23. miR-129 Blocks Secondary Hyperparathyroidism-Inducing Fgf23/αKlotho Signaling in Mice with Chronic Kidney Disease. Xu M; Li H; Bai Y; He J; Chen R; An N; Li Y; Dong Y Am J Med Sci; 2021 May; 361(5):624-634. PubMed ID: 33781552 [TBL] [Abstract][Full Text] [Related]
24. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease. Goto S; Nakai K; Kono K; Yonekura Y; Ito J; Fujii H; Nishi S Clin Exp Nephrol; 2014 Dec; 18(6):925-31. PubMed ID: 24578219 [TBL] [Abstract][Full Text] [Related]
25. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption. Phelps KR; Mason DL Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023 [TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Marsell R; Grundberg E; Krajisnik T; Mallmin H; Karlsson M; Mellström D; Orwoll E; Ohlsson C; Jonsson KB; Ljunggren O; Larsson TE Eur J Endocrinol; 2008 Jan; 158(1):125-9. PubMed ID: 18166826 [TBL] [Abstract][Full Text] [Related]
27. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome]. Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009 [TBL] [Abstract][Full Text] [Related]
29. Association between circulating fibroblast growth factor-23 and age-related cardiovascular-renal parameters in a healthy Chinese population. Wang N; Bai X; Jin B; Han W; Sun X; Chen X Geriatr Gerontol Int; 2017 Aug; 17(8):1221-1231. PubMed ID: 27427468 [TBL] [Abstract][Full Text] [Related]
30. Regulation of fibroblast growth factor-23 in chronic kidney disease. Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652 [TBL] [Abstract][Full Text] [Related]
32. FGF23 and the parathyroid glands. Silver J; Naveh-Many T Pediatr Nephrol; 2010 Nov; 25(11):2241-5. PubMed ID: 20526631 [TBL] [Abstract][Full Text] [Related]
33. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Spatz C; Roe K; Lehman E; Verma N Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446 [TBL] [Abstract][Full Text] [Related]
34. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086 [TBL] [Abstract][Full Text] [Related]
35. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients]. Gan L; Zhou Q Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep; 42(9):1058-1065. PubMed ID: 28989152 [TBL] [Abstract][Full Text] [Related]
36. Serum fibroblast growth factor 23 concentrations in dogs with chronic kidney disease. Dittmer KE; Perera KC; Elder PA Res Vet Sci; 2017 Oct; 114():348-350. PubMed ID: 28667925 [TBL] [Abstract][Full Text] [Related]
37. Fortified phosphorus‑lowering treatment through administration of lanthanum protects against vascular calcification via regulation of FGF23 in chronic kidney disease. Jiang J; Li Y; Zheng D; Wang Z; Zhou H; Liu G Int J Mol Med; 2020 Nov; 46(5):1783-1793. PubMed ID: 32901861 [TBL] [Abstract][Full Text] [Related]
38. Associations of Fibroblast Growth Factor 23 with Markers of Inflammation and Leukocyte Transmigration in Chronic Kidney Disease. Wallquist C; Mansouri L; Norrbäck M; Hylander B; Jacobson SH; Larsson TE; Lundahl J Nephron; 2018; 138(4):287-295. PubMed ID: 29301137 [TBL] [Abstract][Full Text] [Related]
39. Potential ototoxicity of aluminum in hemodialysis patients. Chu PL; Wu CC; Hsu CJ; Wang YT; Wu KD Laryngoscope; 2007 Jan; 117(1):137-41. PubMed ID: 17202943 [TBL] [Abstract][Full Text] [Related]
40. Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. Ibrahim S; Rashed L Int Urol Nephrol; 2009; 41(1):163-9. PubMed ID: 18839328 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]